Evidence map›Paper›PMID 39588887›Full record

ArticleThe New England journal of medicine2024

The Duffy Null Phenotype - Addressing a Source of Discrimination in Cancer Care.

Andrew Hantel, Stephen P Hibbs, Lauren E Merz, Gregory A Abel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The New England journal of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Guideline
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Andrew HantelFrom the Dana-Farber Cancer Institute (A.H., L.E.M., G.A.A.), and the Center for Bioethics (A.H., G.A.A.), Harvard Medical School (A.H., L.E.M., G.A.A.) - both in Boston; and the Wolfson Institute of Population Health, Queen Mary University of London, London (S.P.H.).
Stephen P HibbsFrom the Dana-Farber Cancer Institute (A.H., L.E.M., G.A.A.), and the Center for Bioethics (A.H., G.A.A.), Harvard Medical School (A.H., L.E.M., G.A.A.) - both in Boston; and the Wolfson Institute of Population Health, Queen Mary University of London, London (S.P.H.).
Lauren E MerzFrom the Dana-Farber Cancer Institute (A.H., L.E.M., G.A.A.), and the Center for Bioethics (A.H., G.A.A.), Harvard Medical School (A.H., L.E.M., G.A.A.) - both in Boston; and the Wolfson Institute of Population Health, Queen Mary University of London, London (S.P.H.).
Gregory A AbelFrom the Dana-Farber Cancer Institute (A.H., L.E.M., G.A.A.), and the Center for Bioethics (A.H., G.A.A.), Harvard Medical School (A.H., L.E.M., G.A.A.) - both in Boston; and the Wolfson Institute of Population Health, Queen Mary University of London, London (S.P.H.).

Funding

Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel InterventionK08CA273043 · NCI · DANA-FARBER CANCER INST · PI Andrew Hantel · 2022 to 2026
$1.2M
NCI NIH HHS K08 CA273043
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39588887
PMCPMC11949102

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.